Rivaroxaban: An Affordable and Effective Alternative in Cancer-Related Thrombosis? | Zendy

Flávia Dias Xavier | Zendy; Paulo M. Hoff | Zendy; Maria Ignez Braghiroli | Zendy; Ana Carolina Carvalho Rocha Paterlini | Zendy; Karla Teixeira Souza | Zendy; Luiza Dib Batista Bugiato Faria | Zendy; Fernando Sérgio Blumm Ferreira | Zendy; Karime Kalil Machado | Zendy; Gustavo dos Santos Fernandes | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Rivaroxaban: An Affordable and Effective Alternative in Cancer-Related Thrombosis?

Author(s) -

Flávia Dias Xavier,

Paulo M. Hoff,

Maria Ignez Braghiroli,

Ana Carolina Carvalho Rocha Paterlini,

Karla Teixeira Souza,

Luiza Dib Batista Bugiato Faria,

Fernando Sérgio Blumm Ferreira,

Karime Kalil Machado,

Gustavo dos Santos Fernandes

Publication year - 2016

Publication title -

journal of global oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.002

H-Index - 17

ISSN - 2378-9506

DOI - 10.1200/jgo.2015.002527

Subject(s) - rivaroxaban , medicine , low molecular weight heparin , thrombosis , vitamin k antagonist , pulmonary embolism , cancer , venous thrombosis , retrospective cohort study , anticoagulant , surgery , gastroenterology , warfarin , atrial fibrillation

Venous thromboembolic events (VTEs) are common and potentially fatal complications in cancer patients, and they are responsible for the second most common cause of death. Low molecular weight heparin (LMWH) is the gold-standard treatment, but the costs involved limit its use, especially in developing countries. Recently, the oral anticoagulant rivaroxaban, which directly inhibits factor Xa, was approved for VTE treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research